Research
Hormonal
Skin pigmentation (melanin) acts as a natural sunscreen, reducing the efficiency of cutaneous vitamin D3 synthesis, requiring darker-skinned individuals to have longer sun exposure to achieve similar vitamin D levels as lighter-skinned individuals.
If you have darker skin, you may need more time in the sun to produce adequate vitamin D compared to those with lighter skin. Consider this when evaluating your sun exposure habits.
GoodQualifiesHIGH confidence
However even though Africans have extremely dark heavily pigmented skin a small amount of UVB radiation is able to penetrate into the epidermis to produce vitamin D3. This was demonstrated when adult whites (skin type 2) and blacks (skin type 5) were exposed to the same amount of UVB radiation in a tanning bed. Whereas the white adults raised their blood levels of vitamin D3 more than 30 fold the black adults demonstrated no significant increase in their blood levels of vitamin D3. However when the black adults were exposed to 5 times more UVB radiation, they increased their blood level by about 15-fold.
Why this rating
Supported by specific comparative studies cited in the review.
Source
Sunlight and Vitamin D
Matthias G. Wacker et al. · Dermato-Endocrinology · 2013
DOI 10.4161/derm.24494
narrative_reviewCited 1,128×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sensible sun exposure produces vitamin D3 in the skin, which is metabolized into 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, regulating calcium/phosphate metabolism and influencing chronic disease risk (autoimmune, cancer, cardiovascular, infectious, schizophrenia, type 2 diabetes).Good
- Aging significantly decreases the skin's capacity to produce vitamin D3, requiring older adults to have greater sun exposure or supplementation to maintain healthy vitamin D levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →